LENZ Therapeutics (LENZ) Price & Analysis

Compare

244 Followers

LENZ Stock Chart & Stats

Day’s Range― - ―

52-Week Range$16.54 - $41.70

Previous CloseN/A

Volume24.39K

Average Volume (3M)586.16K

Market Cap

$1.10B

Enterprise Value$614.42M

Total Cash (Recent Filing)$209.52M

Total Debt (Recent Filing)$1.05M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Nov 05, 2025

EPS Estimate

-0.69

Last Dividend Ex-Date

Mar 22, 2024

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding28,522,097

10 Day Avg. Volume669,812

30 Day Avg. Volume586,156

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)3.01

Price to Sales (P/S)0.00

P/FCF Ratio-10.26

Enterprise Value/Market Cap0.56

Enterprise Value/Revenue121.28

Enterprise Value/Gross Profit123.20

Enterprise Value/Ebitda-9.93

Forecast

1Y Price Target

$49.50

Price Target Upside28.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Market StrategyManagement’s launch strategy looks promising with label in hand.

Product LaunchLENZ has announced FDA approval of lead product LNZ-100, now branded VIZZ, and notably a week earlier than expected, an upside surprise.

Sales And MarketingThe company is offering a discount on a 3-month supply, which should drive adoption of this product.

Bears Say

Reporting ChallengesEarly launch metrics may face interpretability issues due to limitations around reporting of e-pharmacies.

LENZ Therapeutics News

Lenz Therapeutics price target raised to $53 from $44 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Lenz Therapeutics (LENZ) to $53 from $44 and...

25d ago

LENZ

Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lenz Therapeutics (LENZ) to $56 from $48 and keeps a...

27d ago

LENZ

Lenz Therapeutics price target raised to $52 from $49 at Citi

Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $52 from $49 and keeps a Buy...

27d ago

LENZ

Lenz Therapeutics announces FDA approval of Vizz eye drop

Lenz Therapeutics (LENZ) announced the FDA approved Vizz 1.44%, the first and only FDA-approved aceclidine-based eye drop for...

28d ago

LENZ

LENZ Therapeutics trading resumes

16:30 EDT LENZ Therapeutics (LENZ) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

28d ago

LENZ

LENZ Therapeutics trading halted, news pending

16:01 EDT LENZ Therapeutics (LENZ) trading halted, news pending Published first on TheFly – the ultimate source for...

28d ago

LENZ

Lenz Therapeutics price target raised to $49 from $45 at Citi

Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $49 from $45 and keeps a Buy...

28d ago

LENZ

Lenz Therapeutics reports Q2 EPS (53c), consensus (54c)

Reports Q2 revenue $5M, consensus $714.29k. “As our PDUFA target action date is rapidly approaching, we are encouraged...

29d ago

LENZ

Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops

LENZ Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on August 1. Analyst Marc...

23d ago

LENZ

Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential

LENZ Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from...

27d ago

LENZ

LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop

LENZ Therapeutics ( ($LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA...

28d ago

LENZ

LENZ Therapeutics’ LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market Positioning

Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on LENZ Therapeutics and keeping the price target...

28d ago

LENZ

Lenz Therapeutics Prepares for LNZ100 Launch

Lenz Therapeutics, Inc. ( ($LENZ) ) has released its Q2 earnings. Here is a breakdown of the information...

28d ago

LENZ

LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on LENZ stock, giving a Buy rating...

29d ago

LENZ

LENZ FAQ

What was LENZ Therapeutics’s price range in the past 12 months?

LENZ Therapeutics lowest stock price was $16.54 and its highest was $41.70 in the past 12 months.

What is LENZ Therapeutics’s market cap?

LENZ Therapeutics’s market cap is $1.10B.

When is LENZ Therapeutics’s upcoming earnings report date?

LENZ Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.

How were LENZ Therapeutics’s earnings last quarter?

LENZ Therapeutics released its earnings results on Jul 30, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.61 by $0.08.

Is LENZ Therapeutics overvalued?

According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does LENZ Therapeutics pay dividends?

LENZ Therapeutics pays a Notavailable dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here

What is LENZ Therapeutics’s EPS estimate?

LENZ Therapeutics’s EPS estimate is -0.69.

How many shares outstanding does LENZ Therapeutics have?

LENZ Therapeutics has 28,522,097 shares outstanding.

What happened to LENZ Therapeutics’s price movement after its last earnings report?

LENZ Therapeutics reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.61. Following the earnings report the stock price went down -2.873%.

Which hedge fund is a major shareholder of LENZ Therapeutics?

Currently, no hedge funds are holding shares in LENZ

LENZ Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-26.25%

Trailing 12-Months

Asset Growth

7.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

LENZ Therapeutics

LENZ Therapeutics (LENZ) is a biopharmaceutical company focused on developing innovative treatments for eye diseases. The company operates in the healthcare sector, specifically targeting ophthalmology, with a primary emphasis on developing therapies for presbyopia and other vision-related disorders. LENZ leverages cutting-edge science and technology to create novel therapeutics that address unmet medical needs in the field of eye care.

LENZ Therapeutics (LENZ) Earnings & Revenues

Historic Earnings Reports

LENZ Company Deck

LENZ Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment overall, with significant progress made towards the launch of LNZ100 and strong financial health. While there are challenges in increased operating and SG&A expenses, the company's strategic initiatives and preparations for the product launch have been well-received. The company is on track for an important year ahead with its upcoming product launch.View all LENZ earnings summaries

LENZ Stock 12 Month Forecast

Average Price Target

$49.50

▲(28.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","61":"$61","25.75":"$25.8","37.5":"$37.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,25.75,37.5,49.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.96,32.27076923076923,34.581538461538464,36.892307692307696,39.20307692307692,41.51384615384616,43.824615384615385,46.135384615384616,48.44615384615385,50.75692307692308,53.06769230769231,55.378461538461536,57.689230769230775,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.96,31.463076923076922,32.966153846153844,34.46923076923077,35.972307692307695,37.47538461538461,38.97846153846154,40.48153846153846,41.98461538461538,43.487692307692306,44.99076923076923,46.49384615384615,47.996923076923075,{"y":49.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.96,30.424615384615386,30.88923076923077,31.353846153846156,31.818461538461538,32.283076923076926,32.747692307692304,33.21230769230769,33.676923076923075,34.14153846153846,34.606153846153845,35.07076923076923,35.535384615384615,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.29,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >